VivoSeq
Oncology

Biliary Tract Cancer

158

Pipeline Programs↗

84

Active Trials↗

67

Companies Involved↗

Biliary Tract Cancer is a highly competitive landscape with 158 programs across 67 companies. The most active players are Lee's Pharmaceutical Limited, Fujifilm Pharmaceuticals U.S.A., Inc., Gynecologic Oncology Group. 3 therapies are approved with 30 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

50/100

Mech. Concentration

6/100

Completion Rate

81/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Lee's Pharmaceutical Limited

1 program

Phase 1F

Fujifilm Pharmaceuticals U.S.A., Inc.

1 program

Phase 1G

Gynecologic Oncology Group

1 program

Phase 1O

OBI Pharma, Inc

1 program

Phase 1Sanofi logo

Sanofi

4 programs

Phase 2Pfizer logo

Pfizer

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical4

Nab-Paclitaxel Plus Gemcitabine-Cisplatin

CHA University

Gemcitabin

German Cancer Research Center

PD-1/PD-L1 Inhibitor

Second Affiliated Hospital of Soochow University

Surufatinib Toripalimab

The Affiliated Hospital of Xuzhou Medical University

Phase 114

Nab-Paclitaxel

Bristol-Myers Squibb

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Regorafenib

Bayer

Gemcitabine Hydrochloride

Gynecologic Oncology Group

BIBW 2992

Boehringer Ingelheim

Phase 2107

Pyrotinib

Hengrui Therapeutics, Inc.

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Rucaparib

Bristol-Myers Squibb

Olaparib

AstraZeneca

Toripalimab

Coherus Oncology, Inc.

Phase 330

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Ivonescimab

Summit Therapeutics

Fluorouracil

Elorac, Inc.

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Gemcitabine

Johnson & Johnson

Approved3

Abemaciclib

Eli Lilly

Pemigatinib

Incyte

Docetaxel

Avyxa

Analysis

Modality Breakdown

81%

Small molecule

162 of 201 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody3517%Antibody–drug conjugate31%Cell therapy1<1%

Small molecule leads; the ring shows all 201 classified programs, each share of the total. Modality classified for 99% of 209 pipeline programs.

Analysis

Trial Status

211

clinical trials

Completed72 · 34%
Recruiting42 · 20%
Unknown status37 · 18%
Active, not recruiting21 · 10%
Not yet recruiting21 · 10%
Terminated10 · 5%
Other8 · 4%

Clinical Trials

Trial Activity

211 trials

Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07025174·60 enrolled
A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer
Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT06978114·46 enrolled
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy
Recruiting·—·Phase 2·NCT05222971·62 enrolled
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
Recruiting·TTata Memorial Centre·Phase 3·NCT07062263·220 enrolled
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Recruiting·—·Phase 2·NCT07135544·37 enrolled
MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer
Recruiting·—·N/A·NCT07156058·204 enrolled
Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer
Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07159204·100 enrolled
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
Recruiting·UUNICANCER·Phase 2·NCT06529718·72 enrolled
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06001658·27 enrolled
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Recruiting·—·Phase 2·NCT06708858·35 enrolled
A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
Recruiting·Suzhou Suncadia Biopharmaceuticals Co., Ltd. logoSuzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07229625·604 enrolled
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT06413745·65 enrolled
Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06280508·40 enrolled
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Recruiting·—·Phase 2·NCT07146646·27 enrolled
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT06546969·15 enrolled
Page 1 of 15

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)